Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eiger BioPharmaceuticals Inc (Eiger), formerly known as Celladon Corp, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of innovative therapies. The company's pipeline products include Avexitide which treats post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI); Lonafarnib/Ritonavir which targets hepatitis delta virus infection; Zokinvy for progeria. It serves for the healthcare industry, specifically for the treatment of rare and ultra-rare diseases. Eiger is headquartered in Palo Alto, California, the US.
Headquarters
United States of America
Address
2155 Park Boulevard, Palo Alto, California, 94306-1543
Website
www.eigerbio.com
Telephone
1 650 2726138
No of Employees
25
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$15.8M
Eiger BioPharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Zokinvy |
| Avexitide - Post-Bariatric Hypoglycemia (PBH) and Congenital Hyperinsulinism (HI) | |
| Lonafarnib/Ritonavir - Hepatitis Delta Virus Infection | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Eiger BioPharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Acadia Pharmaceuticals Inc | XOMA Royalty Corp | Arena Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Palo Alto | Cambridge | San Diego | Emeryville | New York City |
| State/Province | California | Massachusetts | California | California | New York |
| No. of Employees | 25 | 2,230 | 653 | 13 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas J. Dietz, PhD | Director; Chairman | Executive Board | 2015 | 60 |
| David Apelian | Chief Executive Officer; Director | Executive Board | 2017 | 58 |
| William G. Kachioff | Chief Financial Officer | Senior Management | 2023 | 57 |
| James Vollins | General Counsel; Secretary - Corporate; Chief Compliance Officer | Senior Management | 2023 | 55 |
| Christopher Kurtz | Chief Technical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer